These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30848748)

  • 1. [Immunomodulator drugs for the treatment of multiple myeloma].
    Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
    Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
    Srkalovic G; Hussein M
    Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immunomodulatory drugs in myeloma.
    Lacy MQ
    Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
    Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
    Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide - current understanding of mechanistic properties.
    Tageja N
    Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
    Jackson GH; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Wilson J; Taylor C; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Jenner MW; Cook G; Russell NH; Drayson MT; Kaiser MF; Owen RG; Gregory WM; Davies FE; Morgan GJ;
    Br J Haematol; 2021 Mar; 192(5):853-868. PubMed ID: 32656799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA; Becker PS; Bensinger W
    Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
    Rasche L; Einsele H; Nitschmann S
    Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
    Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
    Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.